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PURPOSE. The purpose of this study was to investigate fundus autofluorescence lifetimes in
patients with choroideremia and to identify tissue-specific lifetime characteristics and
potential prognostic markers.
METHODS. Autofluorescence lifetimes of the retina were measured in two spectral channels
(498–560 nm and 560–720 nm) in patients with choroideremia and age-matched healthy
controls. Furthermore, autofluorescence intensities and spectral-domain optical coherence
tomography (OCT) data were acquired and compared to fundus autofluorescence lifetime
data.
RESULTS. Sixteen eyes from 8 patients with advanced choroideremia (mean 6 SD age, 55 6 13
years) were included in this study and compared with 10 age-matched healthy participants.
Whereas fundus autofluorescence intensity measurement identified areas of remaining retinal
pigment epithelium (RPE), autofluorescence lifetime maps identified areas with remaining
photoreceptor layers in OCT but RPE atrophy. In these areas, mean (6SEM) lifetimes were
567 6 59 ps in the short and 603 6 49 ps in the long spectral channels (þ98% and þ88%
compared to controls). In areas of combined RPE atrophy and loss of photoreceptors,
autofluorescence lifetimes were significantly prolonged by 1116 6 63 ps (þ364%) in the
short and by 915 6 52 ps (þ270%) in the long spectral channels compared with controls.
CONCLUSIONS. Because autofluorescence lifetimes identify areas of remaining photoreceptors
in the absence of RPE, this imaging modality may be useful to monitor disease progression in
the natural course of disease and in context of potential future therapeutic interventions.
Keywords: choroideremia, FLIO, fluorescence lifetimes, fundus autofluorescence, retinal
dystrophies, retinal imaging
Choroideremia (CHM) is a rare hereditary retinal diseaseleading to progressive degeneration of the choroid, the
retinal pigment epithelium (RPE), and the retina due to a
mutation of the CHM gene located on the X chromosome.
Because of its X-linked inheritance pattern, CHM primarily
affects male subjects with an estimated prevalence of approx-
imately 1:50,000, but female patients may be affected in a
mosaic disease pattern.1–3 The CHM gene (Xq21.2) encodes a
ubiquitously expressed protein (Rab escort protein [REP-1])
which enables posttranslational modification of Rab proteins.
This protein modification pathway is essential for intracellular
vesicular and membrane trafficking pathways.2 Systemically, no
other effects of the deficient REP-1 is observed because the
autosomal inherited REP-2 can compensate for the deficient
REP-1.3
CHM is diagnosed clinically by the typical fundus appear-
ance and the inheritance pattern and can be confirmed by
genetic analysis.1 Patients typically report onset of night
blindness during the first decade followed by progressive loss
of peripheral vision. Due to the slow progression of disease, the
central fovea is often preserved until late disease stages (50 to
70 years of age). Finally, CHM can result in total blindness when
all remaining photoreceptors—RPE—island complexes have
degenerated.1 The ocular fundus typically has a pale appear-
ance due to the exposure of the underlying sclera after
progressive loss of the outer retina, the RPE and the choroidal
vessels.4 Typically, the remaining islands with preserved RPE
appear as areas with normal or increased autofluorescence
intensity due to lipofuscin accumulation, whereas areas with
RPE atrophy are characterized by hypoautofluorescence.1,5
Whereas fundus autofluorescence intensity is a good
indicator for lipofuscin content and thus RPE integrity, fundus
autofluorescence lifetime imaging is a relatively novel tech-
nique in clinical use for noninvasive identification and
quantification of specific metabolic conditions within the retina
in different retinal diseases.6–10 The method is based on
preliminary work of Schweitzer et al.,11–13 who adapted the
technique for in vivo measurement in the human eye. The
fluorescence lifetime describes the time span a natural retinal
fluorophore spends at its higher energy level after excitation
with a blue laser light before it returns to its ground level of
energy under emission of autofluorescence.
In this study, we analyzed fundus autofluorescence lifetimes
in patients with CHM and investigated potential changes of
fluorescence lifetimes during follow-up examinations.
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METHODS
This prospective study was performed with the approval of the
local ethics committee and was carried out in accordance with
the International Ethical Guidelines for Biomedical Research
involving Human Subjects (Council for International Organiza-
tions of Medical Sciences). It is registered at ClinicalTrials.gov
(NCT01981148) under the title Measurement of Retinal
Autofluorescence with a Fluorescence Lifetime Imaging
Ophthalmoscope. All participants were recruited at the
outpatient department at the University Hospital of Bern,
Switzerland, and signed informed consent prior to study entry.
Subjects and Procedures
At every visit, both eyes were investigated. For all study
participants, best corrected visual acuity (using Early Treat-
ment Diabetic Retinopathy Study [ETDRS] letters)14 and
noncontact intraocular pressure (air tonometry) were as-
sessed. A general ophthalmic examination after maximal pupil
dilation using tropicamide, 0.5%, and phenylephrine hydro-
chloride, 2.5%, was performed to exclude other ophthalmic
conditions such as media opacities that might have interfered
with multimodal imaging. The diagnosis of CHM was
confirmed by at least two independent retinal specialists and
was based on the typical fundus appearance, autofluorescence
and optical coherence tomography (OCT) imaging, and family
history. Gene mutations included CHM (REP-1): c.[16-
17dup](p.S7Lfs*6) exon 1 in one patient and CHM (RNA):
Allele 1: c.[1770þ520C>G], p.[A591_*654delinsQMNQ*], Al-
lele 2: [0] in two patients (cousins). All participants underwent
multimodal imaging at every visit with fundus color imaging
(FF 450plus camera; Zeiss, Oberkochen, Germany), OCT, and
autofluorescence (FAF) intensity measurement of the macula
(Spectralis HRAþOCT; Heidelberg Engineering, Heidelberg,
Germany), and fluorescence lifetime imaging ophthalmoscopy
(Heidelberg Engineering).
Fluorescence Lifetime Imaging Ophthalmoscope
The fluorescence lifetime imaging ophthalmoscope is based on
a Heidelberg retina angiograph (HRA) Spectralis system
(Heidelberg Engineering). A 473-nm pulsed laser, raster
scanning of the central fundus with a repetition rate of 80
MHz was used for excitation of retinal autofluorescence.
The total scan duration per eye lasted approximately 90
seconds. A built-in infrared reflectance camera tracks eye
movements and ensures that every fluorescence photon
emitted is recorded at the correct spatial location. These
photons are detected by highly sensitive hybrid photon-
counting detectors (HPM-100-40; Becker & Hickl, Berlin,
Germany) in a short spectral channel (SSC, 498–560) and in
a long spectral channel (LSC, 560–720) and registered by time-
correlated single-photon counting modules (SPC-150; Becker &
Hickl).
Recorded fluorescence lifetime data were analyzed sepa-
rately within the SSC and LSC using SPCImage 4.6 software
(Becker & Hickl). For every location within the 2563256-pixel
grid covering the central 308 of the macula, a decay trace was
built from the recorded single photons, and a bi-exponential
decay function was calculated using a binning factor of 1.
The mean fluorescence lifetime tau mean (Tm) represents
the amplitude weighted mean fluorescence decay time per
pixel and wavelength channel.
Tm ¼ a1 * T1þ a2 * T2
a1þ a2 ð1Þ
Tm for every pixel within the SSC and the LSC consists of a
short decay component, T1, with its relative amplitude (equal
to relative intensity), a1, and a long decay component, T2, with
its relative amplitude, a2, whereby T1 << T2 and a1 >> a2
(a1 ¼ approximately 90%; range, 96% [macular center]–80%
[periphery]; a2¼ approximately 10%; range, 4%–20%).
TABLE 1. Patient Characteristics
Patient Sex Age
Age at Initial
Diagnosis
ETDRS Visual Acuity Area of RPE, mm2 Follow-Up, Months
Right Left Right Left Number Duration
CHM1 M 51 Child 64 84 3.96 6.04 4 27
CHM2 M 44 Child 82 78 26.03 24.2 6 39
CHM3 M 70 33 66 66 1.23 0.69 – –
CHM4 M 51 Child 33 83 0.36 1.4 1 11
CHM5 M 64 30 65 LP* 1.06 0.64 1 12
CHM6 M 32 30 61 75 1.57 1.24 – –
CHM7 M 68 53 60 LP* 0.59 1.72 – –
CHM8 M 56 45 3 64 1.3 1.58 – –
* LP, light perception.
FIGURE 1. Representative fundus autofluorescence lifetime measure-
ment of a patient with CHM. Multimodal imaging with corresponding
CF, IR, FAF intensity, and autofluorescence lifetime images is shown
(CHM patient 2). FLIO SSC, 498 to 560 nm; color scale, 200 to 1000 ps.
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The technical background of the fluorescence lifetime
imaging (FLIO) system as well as the extensive laser safety
calculations provided by Heidelberg Engineering, according to
the International Electrotechnical Commission,15 have been
described previously.7,16
Optical Coherence Tomography Analysis
Findings in color fundus images, FAF, and FLIO were compared
and correlated with measurements on OCT scans. Retinal
pigment epithelium atrophy was defined when enhanced
choroidal signal was present and/or a disruption of the RPE
was visible.
Fluorescence Intensity Data Analysis
Areas with high autofluorescence intensity, corresponding to
remaining islands of retinal pigment epithelium, were marked
manually, using the region overlay device of the Heidelberg Eye
Explorer software.
Fluorescence Lifetime Data Analysis
The mean fluorescence lifetime Tm, the short T1 and the long
T2 decay components with corresponding amplitudes a1 and
a2 were further analyzed using custom-made ‘‘FLIO reader’’
(Artificial Organs Center for Biomedical Engineering Research,
University of Bern, Bern, Switzerland). The FLIO reader builds
mean values from the respective component within the fields
of a standard ETDRS grid (a circle diameter of the central area
of 1 mm; an inner ring of 3 mm; and an outer ring of 6 mm).16
For further analysis, the grid size was adjusted as stated directly
in the text. For measurement of specific areas within FLIO
pictures, images were imported using ImageJ software (version
1.50i; http://imagej.nih.gov/ij/; provided in the public domain
by the National Institutes of Health, Bethesda, MD, USA), and
the borders were manually marked after calibration with a
scaling factor.
Statistical Analysis
Mean 6 standard errors of the mean (SEM) were calculated.
Prism version 6 (GraphPad Software, Inc., La Jolla, CA, USA)
was used for statistical data analysis. Parametric data were
compared using 2-tailed Student’s t-test with a confidence
interval (CI) of 95%. To eliminate dependence of growth rates
from baseline lesion size, a square root transformation was
used to calculate the yearly progression factor17:ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
Follow up Area ðmm2Þ
Baseline Area ðmm2Þ
s
ð2Þ
RESULTS
Sixteen eyes of 8 patients with CHM were included in this
study. The mean 6 SD age was 55 6 13 years (range, 32–70
years of age). All eyes but one were phakic, but there were no
FIGURE 2. Quantitative analysis of retinal autofluorescence lifetimes
in CHM and correlation with optical coherence tomography findings.
(A) Color fundus, FAF intensity, and autofluorescence lifetime image
(SSC color range, 200–1000 ps) of a 51-year-old male (CHM patient 4)
are shown. The right upper image shows an overlay of FAF and FLIO
with the indicated analysis method. Mean fluorescence lifetime values
were averaged for the ETDRS grid center (diameter [d] ¼ 1 mm) and
the inner (d ¼ 3 mm) and the outer (d ¼ 6 mm) ETDRS ring. The
indicated sample size circle (d ¼ 0.2mm) was used for analysis of
specific regions. The purple and green bars represent OCT scan lines
of the OCT scans below (OCT 1 ¼ purple, left side; OCT 2 ¼ green,
right side). Corresponding points are marked with arrows of the
same color (purple or green) within FAF, FLIO, and OCT. The external
limiting membrane (ELM), remaining photoreceptors (PR), and retinal
pigment epithelium (RPE) are marked in OCT scan 2. Areas of intact
RPE (red [shadowing of the choroid below]) and areas with
remaining PR (orange) are marked in the lowest OCT. (B) Mean
fluorescence lifetime values in specific areas of analysis within the
outer ring of the ETDRS grid. RPEþPR, area of intact RPE, PR and
normal retinal layer structure. PR, area without RPE but remaining
photoreceptor and choroidal cell layer. Atrophy, area with complete
chorioretinal atrophy. Data are shown for the short (498–560 nm) and
long (560–720 nm) spectral channel for CHM patients and compared
with age-matched healthy controls (ctrl [gray dots]). n¼16 CHM eyes
and n¼ 10 control subjects. Each data point represents a mean value
of three sample locations (d ¼ 0.2 mm) within the corresponding
area.
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significant lens opacities. Typical fundus appearance of CHM
with remaining small RPE islands was present in all included
eyes. Ten age-matched healthy phakic subjects without
significant lens opacities served as controls (mean 6 SD age:
53 6 9 years; range, 38–70 years of age; P ¼ 0.79). Patients’
characteristics, visual acuity, and morphologic data are
summarized in Table 1.
A representative overview of multimodal imaging per-
formed in patients with CHM including color fundus, infrared
images, OCT, FAF, and FLIO, is shown in Figure 1. The mean
size of areas with bright fundus autofluorescence (remaining
RPE) was 4.6 6 2 mm2 (mean 6 SEM) at baseline (range, 0.36–
26 mm2).T
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FIGURE 3. Correlation of retinal thickness with autofluorescence
lifetimes and optical coherence tomography. Islands of retinal pigment
epithelium (RPE [red dotted lines]) are marked within FAF intensity
images and remaining photoreceptors (orange dashed lines) are
detectable using autofluorescence lifetime imaging (FLIO [SSC]; CHM
patient 1). The two outlines then were superimposed in both the FLIO
and FAF images. The findings are validated on representative OCT
slices from indicated lines. Corresponding areas are marked with a red
dotted line for the border of the RPE island and with an orange dotted
line for the area with remaining photoreceptors. CF, color fundus; IR,
infrared.
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The mean autofluorescence lifetime within specific regions
of interest are summarized in Figure 2 and Table 2.
Fluorescence Lifetimes in Areas of Intact RPE and
Outer Retinal Layers
In a first step, we analyzed differences between autofluores-
cence lifetimes between patients with CHM and healthy
participants within areas of intact RPE identified by preserved
autofluorescence intensity. As in healthy subjects, the shortest
fluorescence lifetimes were generally seen within the macula,
probably originating from macular pigment.9 When we
compared mean fluorescence lifetimes from the central
subfield of the ETDRS grid of CHM patients with those of
healthy age-matched controls, Tmwas prolonged by 93% in the
SSC (498–560 nm) (P ¼ 0.0002) and by 62% in the LSC (560–
720 nm) (P¼ 0.0001). In the area of the inner ETDRS ring, the
differences were 71% and 62% in the SSC and the LSC,
respectively, and 67% and 59% in the outer ETDRS ring,
respectively (all P < 0.0001).
Fluorescence Lifetimes in Areas of Chorioretinal
Atrophy
Areas of chorioretinal atrophy identified by hypoautofluores-
cence in FAF, choroidal signal enhancement, and absence of
the outer nuclear layer in OCT showed a significantly
prolonged Tm with 1422 ps (464% of control values) in the
SSC and 1253 ps (370%) in the LSC compared to corresponding
retinal areas in age-matched controls (P < 0.0001).
Fluorescence Lifetimes in Areas of RPE Atrophy
but Remaining Outer Retinal Layers
Areas of relatively preserved fluorescence intensity in FAF
images corresponded exactly to areas of intact RPE in OCT
(Figs. 2, 3). However, these RPE borders were not directly
identifiable within the Tm lifetime map. The outer borders of
the areas with shorter autofluorescence lifetimes correlated to
areas with remaining photoreceptor cell layer, independent of
the presence or absence of the underlying RPE. The mean area
of these islands with shorter lifetimes was 17.9 6 3.3 mm2
(range, 1.6–44.2 mm2).
Autofluorescence lifetimes in areas with RPE atrophy but
remaining photoreceptor layer in OCT were prolonged by 33%
respectively, 24% in the central ETDRS area, by 16% in the
inner ring, and by 23% respectively, 13% in the outer ring (SSC
respectively, LSC) compared to corresponding retinal areas in
age-matched controls. The FAF area-to-FLIO area ratio within
the same eye showed a range of 1:1.8 to 1:77 (e.g., see Figs. 1–
3).
Analysis of Individual Fluorescence Lifetime
Components
For detailed analysis, the amplitude weighted mean fluores-
cence lifetime value Tmwas divided into its single components
T1 (short decay component) and T2 (long decay component).
Data were visualized in a two-dimensional (2-D) dot plot with
T1 on the x-axis and T2 on the y-axis (Fig. 4). In both the SSC
and the LSC, the remaining retinal islands with intact RPE and
PR featured a particularly short decay component T2. The
surrounding retina was represented by one single lifetime
cluster. Thereby, the area with remaining photoreceptor layer
featured the shortest decay component T1, followed by the
retinal vessels and the optic nerve head. The surrounding
retina with bare chorioscleral structures featured the longest
T2, contributing to the long Tm values. In follow-up
examinations, the lifetime cluster originating from the remain-
ing RPE islands decreased (Fig. 5B).
Follow-up Examinations
Follow-up examinations of 50% of the eyes (n ¼ 8) were
performed with repetitive FLIO measurements up to 6 times
over 3 years to assess disease-associated changes over time. In
8 eyes of 4 patients with CHM, a follow-up examination was
performed after 1 year. Two patients were examined six times
within the last 3 years. Even though there was no significant
change in the assessed best visual acuity, all patients reported a
slight decrease (and in one case, a severe reduction) of their
vision within this period of time. Whereas retinal changes were
FIGURE 4. Analysis of individual lifetime components and spatial distribution in patients with CHM. Color fundus, FAF intensity, and mean
fluorescence lifetime (Tm [LSC]) images (CHM patient 8). Corresponding distribution histograms of the short decay component T1 versus the long
decay component T2 (Equation 1) are shown. Spatial distribution of different lifetime clusters as follows: (1) retinal pigment epithelium with short
T1 and short T2: (2) photoreceptors with short T1 and midrange T2; and (3) chorioretinal atrophy with long T1 and long T2.
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FIGURE 5. Longitudinal changes of fluorescence lifetimes in patients with CHM. Follow-up examinations with fluorescence lifetime imaging
ophthalmoscopy (CHM patient 2). (A) Corresponding FAF intensity, FLIO (SSC) and OCT images are shown. Corresponding points are marked with
arrows of the same color (purple or green) within FAF, FLIO, and OCT. A moderate reduction of the area with normal retinal pigment epithelium in the
FAF image as well as the area of remaining photoreceptors, is mirrored by a decrease of short retinal fluorescence lifetimes in the FLIO image is shown.
(B) Two-dimensional distribution histograms (T1 versus T2 [Equation 1]) are shown for the baseline as well as for the follow-up examination. There is a
moderate reduction of the short lifetime cloud (white arrows). (C) A general prolongation of mean retinal autofluorescence lifetimes of the central area
and the inner ring of the ETDRS grid is measured in the follow-up examinations (n¼ 8 eyes of 4 patients, one color per patient).
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difficult to assess in color fundus images, in the FAF images, the
outer border of the intact retinal islands were clearly
discernible. Within 1 year, the mean area of intact retinal
structure decreased by 7% (0.48 mm2), with a range of 1.7% to
11.1% (0.04–1.73 mm2). The area of short retinal fluorescence
lifetimes decreased by 14% (3.4 mm2). Square root transfor-
mation of the data according to Equation 2 revealed a mean
decrease of 7.9% of the FAF area and 7.6% of the FLIO area.
Over this observation period, Tm was prolonged by 56 6 30
ps (14%) in the SSC and 8 6 7 ps (1.5%) in the LSC within the
central ETDRS circle (Fig. 5). There was an average extension
of autofluorescence lifetimes of 36 ps/year in the RPE islands
and 50 ps/year in areas with RPE atrophy but remaining
photoreceptors and choroid in the SSC.
DISCUSSION
In this report we showed that autofluorescence lifetimes
originating from areas with remaining photoreceptor cell layers
feature short decay times independent of the presence or
absence of the underlying RPE. As such, additional information
can be obtained on the state of photoreceptors in patients with
CHM and may be helpful to further our understanding of the
pathophysiology of this rare disease.
Although the underlying defect in CHM can be specifically
attributed to a mutation within the gene that encodes REP-1
with subsequent retinal degeneration, characteristically for
CHM,18 the exact pathomechanism of this hereditary disease
has not yet been resolved. There is controversy about which
layers are primarily affected by the disease and which undergo
consecutive degeneration. Recently, wave front analysis using
adaptive optics confirmed evidence from previous reports that
the RPE is one primary site of degeneration in CHM.18 In our
current study using FLIO for measurement of autofluorescence
lifetimes of the ocular fundus in CHM, we were able to identify
areas with remaining photoreceptors in the absence of the
RPE. A striking finding is that, in contrast to areas with
photoreceptor atrophy which display very long fluorescence
lifetimes, these areas feature short fluorescence lifetimes. Two
findings associated with short fluorescence lifetimes merit
further discussion. In the first instance, data from other
studies19 and from our previous studies7 suggest that
components of the visual cycle such as all-trans retinal (atRAL)
display very short lifetimes. Under conditions of visual cycle
dysfunction, retinoid cycle by-products have been shown to
accumulate in outer segments of photoreceptor cells and the
RPE.20,21 Therefore, short autofluorescence lifetimes found in
areas of remaining photoreceptors may indicate that there is
some remaining activity of the visual cycle and generation of
visual cycle by-products. This hypothesis is further supported
by findings in a mouse model of retinal detachment where
autofluorescence measurements revealed hyperfluorescent
spots within the area of detached retina which were
spectroscopically similar to the bisretinoids that constitute
RPE lipofuscin.22 This explanation for the short autofluores-
cence lifetimes observed in areas of RPE atrophy, but
remaining photoreceptors are speculative but consistent with
previous hypothesis on the pathophysiology of CHM.
On the other hand, recent data suggest that distinct patterns
of short fluorescence lifetimes within the fovea derive from
macular pigment.9 In patients with CHM, macular pigment
present in the plexiform layers and the photoreceptor axon
layers in areas with RPE atrophy may therefore lead to short
fluorescence lifetimes, at least in the fovea (Fig. 2). It was
previously shown in a case series that macular pigment optical
densities in patients with CHM do not differ from those in age-
matched healthy controls.23 Although we did not quantify this,
this appears to be in keeping with our findings. However, in
cases of advanced chorioretinal atrophy involving the center,
such as seen in Figure 4, the area with short lifetimes
disappears. Thus, the distribution of very short fluorescence
lifetimes within the macular center may be used as a follow-up
parameter and may serve as an indicator of the integrity of the
Henle fiber layer and the outer plexiform layer containing the
macular pigment.
However, even in areas with intact RPE verified by
autofluorescence imaging, fluorescence lifetimes are already
prolonged compared to corresponding areas in age-matched
healthy controls. Accumulation of lipofuscin derivatives,
which have been shown to display long lifetimes (1262
ps),12,24 could explain our findings. This supports the
hypothesis that the RPE might be the primary site of
degeneration.1 Additionally, loss of photoreceptors and con-
comitant decrease of visual cycle by-products may also lead to
longer fluorescence lifetimes in areas with intact RPE. The
latter is supported by adaptive optic findings with cone density
loss in such areas of patchy RPE damage.18 The information
about RPE function and loss of photoreceptors in remaining
RPE islands will be useful to assess disease activity and serve as
control for future therapies in the field of gene therapy.1,4,25
The option to obtain information on individual lifetime
components such as T1 and T2 and the corresponding
amplitudes by 2D plotting of individual lifetime clusters allows
visualization of the distinct aspects of disease progression over
time and will be useful to monitor therapeutic approaches by
quantifying changes in lifetime clusters over time as seen in
Figure 5. Furthermore, FLIO could provide information about
the location where to deliver the subretinal vector deposits: on
one hand to not harm the remaining RPE and on the other
hand having a higher chance to integrate in areas with still
existing photoreceptor cell structures.
CONCLUSIONS
In vivo autofluorescence lifetime measurement can be used for
tissue characterization in CHM. Remaining outer retinal layers
correlate with short fluorescence lifetimes even in the absence
of the retinal pigment epithelium. Prolongation of fluores-
cence lifetimes over time indicates disease progression and
therefore might be used for follow-up of subtle retinal changes.
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